American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results
American Shared Hospital Services (NYSE American: AMS) reported strong Q2 2024 financial results, with revenue increasing 27% year-over-year to $7.1 million. The company realized a gain of $3.7 million from the strategic acquisition of Rhode Island Radiation Therapy Cancer Centers. Net income attributable to AMS was $3.6 million, or $0.55 per diluted share, compared to a net loss of $111,000 in Q2 2023. Adjusted EBITDA increased to $2,010,000. Key highlights include:
- Gamma Knife procedures increased 10% due to strong international volume
- Proton beam radiation therapy revenue decreased 5%
- Cash at June 30, 2024 was $14.5 million
- Signed a joint venture agreement for a Gamma Knife facility in Guadalajara, Mexico
- Started patient treatments at the new Puebla, Mexico center
American Shared Hospital Services (NYSE American: AMS) ha riportato risultati finanziari solidi per il secondo trimestre del 2024, con un aumento dei ricavi del 27% anno su anno a 7,1 milioni di dollari. L'azienda ha realizzato un guadagno di 3,7 milioni di dollari dall'acquisizione strategica dei centri di terapia radioterapica per il cancro del Rhode Island. L'utile netto attribuibile ad AMS è stato di 3,6 milioni di dollari, ovvero 0,55 dollari per azione diluita, rispetto a una perdita netta di 111.000 dollari nel secondo trimestre del 2023. L'EBITDA rettificato è aumentato a 2.010.000 dollari. I principali risultati includono:
- Aumento del 10% nelle procedure Gamma Knife grazie a un forte volume internazionale
- Riduzione del 5% dei ricavi dalla terapia con protoni
- Liquidità al 30 giugno 2024 di 14,5 milioni di dollari
- Firmato un accordo di joint venture per una struttura Gamma Knife a Guadalajara, Messico
- Avviati i trattamenti per i pazienti nel nuovo centro di Puebla, Messico
American Shared Hospital Services (NYSE American: AMS) reportó sólidos resultados financieros para el segundo trimestre de 2024, con un aumento del 27% en los ingresos interanuales a 7.1 millones de dólares. La compañía obtuvo una ganancia de 3.7 millones de dólares por la adquisición estratégica de los Centros de Terapia Radiológica del Cáncer de Rhode Island. La utilidad neta atribuible a AMS fue de 3.6 millones de dólares, o 0.55 dólares por acción diluida, en comparación con una pérdida neta de 111,000 dólares en el segundo trimestre de 2023. El EBITDA ajustado aumentó a 2,010,000 dólares. Los aspectos destacados incluyen:
- Aumento del 10% en los procedimientos de Gamma Knife gracias a un fuerte volumen internacional
- Disminución del 5% en los ingresos por terapia de radiación con protones
- Efectivo al 30 de junio de 2024 fue de 14.5 millones de dólares
- Firma de un acuerdo de joint venture para una instalación de Gamma Knife en Guadalajara, México
- Inicio de tratamientos para pacientes en el nuevo centro de Puebla, México
American Shared Hospital Services (NYSE American: AMS)는 2024년 2분기 재무 결과가 강력하다고 보고하며, 연간 27% 증가한 710만 달러의 매출을 기록했습니다. 회사는 로드 아일랜드 방사선 치료 암 센터의 전략적 인수로 370만 달러의 이익을 실현했습니다. AMS에 귀속되는 순이익은 360만 달러, 즉 희석 주당 0.55 달러로, 2023년 2분기에는 111,000 달러의 순손실을 기록했습니다. 조정된 EBITDA는 2,010,000 달러로 증가했습니다. 주요 하이라이트는 다음과 같습니다:
- 국제적인 수요 증가로 Gamma Knife 시술이 10% 증가했습니다.
- 양성자 방사선 요법 수익은 5% 감소했습니다.
- 2024년 6월 30일 기준 현금은 1450만 달러였습니다.
- 멕시코 과달라하라에 Gamma Knife 시설을 위한 합작 투자 계약 체결
- 새로운 멕시코 푸엥블 센터에서 환자 치료 시작
American Shared Hospital Services (NYSE American: AMS) a annoncé de solides résultats financiers pour le deuxième trimestre 2024, avec une augmentation de 27% des revenus par rapport à l'année précédente, atteignant 7,1 millions de dollars. L'entreprise a réalisé un gain de 3,7 millions de dollars grâce à l'acquisition stratégique des Centres de thérapie par radiation du Rhode Island. Le revenu net attribuable à AMS s'élevait à 3,6 millions de dollars, soit 0,55 dollar par action diluée, contre une perte nette de 111 000 dollars au deuxième trimestre 2023. L'EBITDA ajusté a augmenté pour atteindre 2 010 000 dollars. Les points clés incluent :
- Augmentation de 10% des procédures Gamma Knife grâce à un volume international élevé
- Diminution de 5% des revenus de la thérapie à faisceau de protons
- La trésorerie au 30 juin 2024 était de 14,5 millions de dollars
- Signature d'un accord de coentreprise pour une installation Gamma Knife à Guadalajara, au Mexique
- Début des traitements pour les patients dans le nouveau centre de Puebla, au Mexique
American Shared Hospital Services (NYSE American: AMS) hat im zweiten Quartal 2024 starke Finanzzahlen vorgelegt, mit einem Anstieg der Einnahmen um 27% im Jahresvergleich auf 7,1 Millionen Dollar. Das Unternehmen erzielte einen Gewinn von 3,7 Millionen Dollar aus der strategischen Akquisition der Rhode Island Strahlentherapie-Krebszentren. Der Nettogewinn, der auf AMS entfällt, betrug 3,6 Millionen Dollar oder 0,55 Dollar pro verwässerter Aktie, im Vergleich zu einem Nettoverlust von 111.000 Dollar im zweiten Quartal 2023. Das bereinigte EBITDA stieg auf 2.010.000 Dollar. Zu den wichtigsten Höhepunkten gehören:
- Eine 10%ige Steigerung der Gamma Knife-Verfahren aufgrund eines starken internationalen Volumens
- Die Einnahmen aus Protonenstrahltherapie gingen um 5% zurück
- Der Bargeldbestand am 30. Juni 2024 betrug 14,5 Millionen Dollar
- Unterzeichnung eines Joint-Venture-Vertrags für eine Gamma Knife-Einrichtung in Guadalajara, Mexiko
- Beginn der Patientenbehandlungen im neuen Zentrum in Puebla, Mexiko
- Revenue increased 27% year-over-year to $7.1 million
- Realized a gain of $3.7 million from the acquisition of Rhode Island Radiation Therapy Cancer Centers
- Net income of $3.6 million, or $0.55 per diluted share, compared to a net loss in Q2 2023
- Adjusted EBITDA increased to $2,010,000
- Gamma Knife procedures increased 10% due to strong international volume
- Cash position improved to $14.5 million
- Signed a joint venture agreement for a new Gamma Knife facility in Guadalajara, Mexico
- Started patient treatments at the new Puebla, Mexico center
- Proton beam radiation therapy revenue decreased 5% year-over-year
- Proton beam radiation therapy fractions decreased 10%
- Gamma Knife revenue decreased 9% due to lower average reimbursement
- Gross margin percentage decreased to 35% from 45% in the year-ago period
- Interest expense increased due to higher interest rates and borrowings
Insights
American Shared Hospital Services (AMS) reported a strong Q2 2024 with revenue increasing
While Gamma Knife procedures increased
The expansion of AMS into retail radiation therapy services through the Rhode Island acquisition is a strategic move to diversify revenue streams. The company's international growth, particularly in Ecuador and Peru where they operate the only Gamma Knife systems in those countries, shows promise. The new facility in Puebla, Mexico and the joint venture agreement in Guadalajara further strengthen their international presence.
However, the
- Revenue increases
27% year over year - Reports gain of
$3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers - Now treating patients at the new Puebla, Mexico center
- Conference Call on August 14th at 6:30 pm ET
SAN FRANCISCO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the second quarter ended June 30, 2024.
Second Quarter 2024 and Recent Highlights
- Total revenue in the second quarter was
$7.1 million , an increase of27% from the comparable period in 2023 bolstered by the completion of our acquisition of60% of the equity interest of three Rhode Island radiation therapy facilities in May which accounted for$1.9 million of the increase. Total proton beam radiation therapy revenue decreased5% period-over-period; fractions decreased10% . Gamma Knife procedures increased10% due to strong volume at our international sites, the related Gamma Knife revenue decreased by9% period-over-period due to lower average reimbursement in the quarter. - Gross margin was
$2.5 million , a period-over-period decrease of2% . The gross margin percentage was35% of revenue compared to45% in the year-ago period reflecting the expansion in the retail segment. - Operating income for the second quarter of 2024 increased by
$324,000 compared to second quarter of 2023 primarily due to reduced impaired assets and removal costs. - Net income attributable to American Shared Hospital Services in the second quarter of 2024 was
$3.6 million , or$0.55 per diluted share, compared to a net loss of$111,000 , or$0.02 per diluted share, for the second quarter of 2023. The increase was primarily due to the$3.7 million bargain purchase gain from the acquisition of60% of the equity interest of three Rhode Island radiation therapy facilities. - Adjusted EBITDA, a non-GAAP financial measure, was
$2,010,000 for the second quarter of 2024, compared to$1,938,000 for the second quarter of 2023. The increase was due to the contribution from the Rhode Island facilities. - Cash at June 30, 2024 was
$14.5 million compared to$13.8 million at December 31, 2023. - Signed 1 new order to upgrade an existing customer to a Leksell Gamma Knife Esprit, the latest model.
- Signed a joint venture agreement for Gamma Knife facility in Guadalajara, Mexico, establishes Company’s 4th International Center.
- Announced start of patient treatments at its Radiation Therapy Facility, A.B. Radiocirugía y Radioterapia de Puebla, in Puebla, Mexico.
Ray Stachowiak, CEO and Executive Chairman of American Shared Hospital Services, commented, “With the acquisition of
“Our Q2’2024 was a strong quarter for AMS with improvement in operations and a strong focus on continued execution. Our leasing business also remains solid with the signing of 5 lease extensions over the last 15 months from our base of ten domestic Gamma Knife sites and we have several others in discussion.”
“Additionally, we continue to see international patient volumes growing nicely with the new state-of-the-art Gamma Knife ICON firmly in place, the only Gamma Knife in Ecuador for non-invasive radiosurgery. Our Gamma Knife in Peru, the only Gamma Knife in the country also showed strong results in the second quarter. And in addition to our joint venture agreement for Gamma Knife facility in Guadalajara, Mexico that we recently announced, our international center in Puebla, Mexico has begun treating patients which we expect to be another solid revenue contributor going forward.”
“The second quarter marks a strong start to the year, with revenue growth of
Craig Tagawa, President and Chief Operating Officer, added, “It is extremely gratifying to see our growth strategy taking hold as we expanded our product portfolio and increased our capacity for creative financial solutions. We have continued to see a significant increase the breadth of opportunities for consideration and our sales pipeline remains extremely strong with additional projects in the works. The traction continues to grow and with the strength of our overall business supported by our strong balance sheet and consistent cash flow, we are well positioned for future growth,” concluded Mr. Tagawa.
Financial Results for the Three Months Ended June 30, 2024
For the three months ended June 30, 2024, revenue increased
Second quarter revenue for the Company's proton beam radiation therapy system installed at Orlando Health in Florida decreased
Total proton beam radiation therapy fractions in the second quarter were 1,236 compared to 1,370 proton beam radiation therapy fractions in the second quarter of 2023, a
Total revenue for the Company's Gamma Knife operations decreased by
Total Gamma Knife procedures increased by
Gross margin for the second quarter of 2024 decreased
Selling and administrative costs decreased by
Interest expense was
Operating income for the second quarter was breakeven due to the additional costs related to the closing of the Rhode Island acquisition and other new business opportunities of
Net income attributable to American Shared Hospital Services in the second quarter of 2024 was
Adjusted EBITDA, a non-GAAP financial measure, was
Financial Results for the Six Months Ended June 30, 2024
For the six months ended June 30, 2024, revenue increased
Gamma Knife revenue decreased
Net income attributable to American Shared Hospital Services for the first six months of 2024 was
Adjusted EBITDA, a non-GAAP financial measure, was
Balance Sheet Highlights
At June 30, 2024, cash, cash equivalents, and restricted cash was
Conference Call and Webcast Information
AMS has scheduled a conference call to review its financial results for Wednesday, August 14th at 6:30 pm ET / 3:30 pm PT.
To participate, domestic callers may dial 844.413.3972 and international callers may dial 412.317.5776 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call. A simultaneous Webcast of the call may be accessed through the Company's website, www.ashs.com, or at www.streetevents.com for institutional investors.
A replay of the call will be available at 877.344.7529 or 412.317.0088, access code 8320435, through August 21, 2024. The call will also be available for replay on the Company’s website at www.ashs.com.
About American Shared Hospital Services (NYSE American: AMS)
American Shared Hospital Services (ASHS) is a leading provider of creative financial and turnkey solutions to Cancer Treatment Centers, hospitals, and large cancer networks worldwide. The company works closely with all major global Original Equipment Manufacturers (OEMs) that provide leading edge clinical treatment systems and software to treat cancer using Radiation Therapy and Radiosurgery. The company is vendor agnostic and provides financial support for a wide range of products including MR Guided Radiation Therapy Linacs, Advanced Digital Linear Accelerators, Proton Beam Radiation Therapy Systems, Brachytherapy systems and suites, and through the Company’s subsidiary, GK Financing LLC., the Leksell Gamma Knife product and services. For more information, please visit: www.ashs.com
Safe Harbor Statement
This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and MR/LINAC businesses, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the three month period ended March 31, 2024, the Annual Report on Form 10-K for the year ended December 31, 2023, and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 25, 2024.
Non-GAAP Financial Measure
Adjusted EBITDA, the non-GAAP measure presented in this press release and supplementary information, is not a measure of performance under the accounting principles generally accepted in the United States ("GAAP"). This non-GAAP financial measure has limitations as an analytical tool, including that it does not have a standardized meaning. When assessing our operating performance, this non-GAAP financial measure should not be considered a substitute for, and investors should also consider, income before income taxes, income from operations, net income attributable to the Company, earnings per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability.
EBITDA is a non-GAAP financial measure representing our earnings before interest expense, income tax expense, depreciation, and amortization. We define Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense, depreciation and amortization expense, loss on write down of impaired assets and associated removal costs, bargain purchase gain, and stock-based compensation expense.
We use this non-GAAP financial measure as a means to evaluate period-to-period comparisons. Our management believes that this non-GAAP financial measure provides meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as stock-based compensation expense. We believe that both management and investors benefit from referring to this non-GAAP financial measure in assessing our performance.
Contacts:
American Shared Hospital Services
Ray Stachowiak, Executive Chairman and CEO
rstachowiak@ashs.com
Investor Relations
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
| - Tables Follow – | |||||||||||||||||
| American Shared Hospital Services | |||||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||||
| Summary of Operations Data | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenues | $ | 7,056,000 | $ | 5,568,000 | $ | 12,272,000 | $ | 10,493,000 | |||||||||
| Costs of revenue | 4,588,000 | 3,050,000 | 7,661,000 | 6,067,000 | |||||||||||||
| Gross margin | 2,468,000 | 2,518,000 | 4,611,000 | 4,426,000 | |||||||||||||
| Selling and administrative expense | 1,896,000 | 1,988,000 | 3,775,000 | 3,527,000 | |||||||||||||
| Interest expense | 385,000 | 277,000 | 734,000 | 548,000 | |||||||||||||
| Loss on write down of impaired assets and associated removal costs | 188,000 | 578,000 | 188,000 | 578,000 | |||||||||||||
| Operating (loss) | (1,000 | ) | (325,000 | ) | (86,000 | ) | (227,000 | ) | |||||||||
| Bargain purchase gain, net | 3,679,000 | - | 3,679,000 | - | |||||||||||||
| Interest and other income (loss) | 59,000 | 113,000 | 165,000 | 183,000 | |||||||||||||
| Income (loss) before income taxes | 3,737,000 | (212,000 | ) | 3,758,000 | (44,000 | ) | |||||||||||
| Income tax (benefit) expense | (31,000 | ) | (35,000 | ) | (75,000 | ) | 33,000 | ||||||||||
| Net income (loss) | 3,768,000 | (177,000 | ) | 3,833,000 | (77,000 | ) | |||||||||||
| (Plus) less: Net loss (income) attributable to non-controlling interest | (166,000 | ) | 66,000 | (112,000 | ) | 154,000 | |||||||||||
| Net income (loss) attributable to American Shared Hospital Services | $ | 3,602,000 | $ | (111,000 | ) | $ | 3,721,000 | $ | 77,000 | ||||||||
| Earnings (loss) per common share: | |||||||||||||||||
| Basic | $ | 0.56 | ($ | 0.02 | ) | $ | 0.58 | $ | 0.01 | ||||||||
| Diluted | $ | 0.55 | ($ | 0.02 | ) | $ | 0.57 | $ | 0.01 | ||||||||
| Weighted Average Shares Outstanding: | |||||||||||||||||
| Basic | 6,482,000 | 6,336,000 | 6,467,000 | 6,482,000 | |||||||||||||
| Diluted | 6,583,000 | 6,336,000 | 6,564,000 | 6,465,000 | |||||||||||||
| American Shared Hospital Services | |||||||||||||||||
| Balance Sheet Data | |||||||||||||||||
| Balance Sheet Data | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| 6/30/2024 | 12/31/2023 | ||||||||||||||||
| Cash, cash equivalents and restricted cash | $ | 14,486,000 | $ | 13,808,000 | |||||||||||||
| Current assets | $ | 25,639,000 | $ | 20,456,000 | |||||||||||||
| Total assets | $ | 60,825,000 | $ | 48,162,000 | |||||||||||||
| Current liabilities | $ | 13,336,000 | $ | 10,779,000 | |||||||||||||
| Shareholders' equity, excluding non-controlling interests | $ | 26,542,000 | $ | 22,624,000 | |||||||||||||
| American Shared Hospital Services | |||||||||||||||
| Adjusted EBITDA | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Adjusted Results | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net income (loss) | $ | 3,602,000 | $ | (111,000 | ) | $ | 3,721,000 | $ | 77,000 | ||||||
| Plus (less): | Income tax (benefit) expense | (31,000 | ) | (35,000 | ) | (75,000 | ) | 33,000 | |||||||
| Interest expense | 385,000 | 277,000 | 734,000 | 548,000 | |||||||||||
| Interest (income) | (77,000 | ) | (110,000 | ) | (189,000 | ) | (197,000 | ) | |||||||
| Depreciation and amortization expense | 1,523,000 | 1,242,000 | 2,857,000 | 2,609,000 | |||||||||||
| Stock-based compensation expense | 99,000 | 97,000 | 197,000 | 193,000 | |||||||||||
| Bargain purchase gain, net | (3,679,000 | ) | - | (3,679,000 | ) | - | |||||||||
| Loss on write down of impaired assets and associated removal costs | 188,000 | 578,000 | 188,000 | 578,000 | |||||||||||
| Adjusted EBITDA | $ | 2,010,000 | $ | 1,938,000 | $ | 3,754,000 | $ | 3,841,000 | |||||||
FAQ
What was American Shared Hospital Services' (AMS) revenue for Q2 2024?
How much did AMS gain from the Rhode Island Radiation Therapy Cancer Centers acquisition?
What was AMS's net income per share for Q2 2024?
How did Gamma Knife procedures perform for AMS in Q2 2024?
What was AMS's cash position as of June 30, 2024?
